Noninvasive tests have significantly transformed the diagnosis and management of metabolic dysfunction-associated fatty liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), conditions often overlooked due to their vague symptoms and limited public awareness. These tests enable effective assessment and monitoring of liver health without the need for invasive liver biopsy.
Initial Screening: FIB-4 and Advancements
The fibrosis-4 (FIB-4) index, calculated using age, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and platelet count, is the first-line screening method recommended by major clinical guidelines for assessing advanced fibrosis. Elevation in FIB-4 results prompts second-line noninvasive assessment for a more accurate diagnosis. While FIB-4 is convenient, affordable, and widely available, its diagnostic accuracy may not be optimal for all patients.
For those or settings where imaging-based tests are unavailable or inaccessible, the enhanced liver fibrosis (ELF) test can serve as a more accurate alternative. However, the specific biomarkers and risk thresholds for the ELF test are not provided in the source.
Imaging-Based Tests: Precision and Convenience
Imaging techniques like vibration-controlled transient elastography (VCTE) and magnetic resonance imaging (MRI) provide precise diagnosis of fibrosis stages and liver fat quantification. VCTE measures liver stiffness using ultrasound shear waves and can also estimate liver fat through the controlled attenuation parameter (CAP). It is a rapid, point-of-care imaging modality that offers wide clinical applicability. MRI enables assessment of liver fibrosis using magnetic resonance elastography (MRE), which combines MRI with low-frequency mechanical waves to generate quantitative liver stiffness maps. However, the source does not mention the specific performance of MRE in severely obese patients.
Related: INSR Gene Variant Reduces Metabolic Risk
Magnetic resonance imaging proton density fat fraction (MRI-PDFF) provides precise liver fat quantification but is not called the reference standard in the source. It measures the ratio of fat protons to the total number of mobile protons from both fat and water, offering a precise fat percentage score for the entire scanned liver.
Expert consensus agrees that combining modalities enhances diagnostic confidence. Clinicians should consider clinical risk, test availability, and discordant findings when selecting a test. A stepwise strategy using simple serum scores followed by elastography or advanced composite tests improves diagnostic accuracy and referral decisions. Imaging-based NITs offer excellent performance for fibrosis staging and longitudinal assessment, supporting better disease monitoring and management.
Test choice should reflect clinical risk, availability, and discordant findings. Simple blood-based risk stratification tools can be followed by VCTE for additional fibrosis assessment in primary care or other non-hepatology settings. However, in high-risk patients, more accurate tests may be necessary to improve diagnostic confidence and inform appropriate patient management. Each test has its pros and cons, requiring clinicians to weigh these factors and develop suitable care plans tailored to individual patient needs.